Medicus Pharma Ltd. (NASDAQ: MDCX) issued clarification regarding previously reported topline results from its Phase 2 clinical study of SKNJCT-003 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE